6 hours Down -22.94% in 4 Weeks, Here’s Why You Should You Buy the Dip in BioMarin (BMRN) Zacks
BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biomarin Pharma (BMRN) · Earnings · Wall Street